Dynavax Technologies | DVAX - Current Assets


Dynavax Technologies reported $814.33M in Current Assets for its fiscal quarter ending in September of 2025.



Current Assets Change Date
AbbVie USD 29.06B 523M Dec/2025
Adma Biologics USD 466.51M 63.86M Dec/2025
Agenus USD 133.44M 514K Dec/2025
Amgen USD 29.06B 1.17B Dec/2025
AstraZeneca USD 28.72B 1.22B Dec/2025
Biogen USD 8.97B 37.5M Dec/2025
BioMarin Pharmaceutical USD 3.95B 98.95M Dec/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
Glaxosmithkline GBP 23.59B 390.44M Dec/2025
Merck USD 47.56B 10.49B Sep/2025
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Nektar Therapeutics USD 281.36M 94.79M Sep/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
Novartis USD 30.46B 2.26B Dec/2025
Pfizer USD 46.92B 3.22B Sep/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Roche Holding CHF 38.73B 3.03B Dec/2025
Sarepta Therapeutics USD 2.54B 184.37M Dec/2025
TG Therapeutics USD 630.76M 31M Dec/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025